Literature DB >> 9822651

Differential effects of integrin alpha chain mutations on invasin and natural ligand interaction.

E S Krukonis1, P Dersch, J A Eble, R R Isberg.   

Abstract

To determine if recognition of the Yersinia pseudotuberculosis invasin protein and natural substrates requires identical integrin residues, a region of the human alpha3 integrin chain predicted to be involved in substrate adhesion was targeted for mutation. One point mutation located in a region of the third N-terminal repeat of the alpha3 chain, alpha3-W220A, failed to promote adhesion to the natural alpha3 beta1 substrate epiligrin but maintained near wild type levels of adhesion to invasin. A second nearby mutation, alpha3-Y218A, which showed no detectable adhesion to epiligrin, was only partially attenuated for invasin binding as well as invasin-mediated bacterial uptake. A third substitution, alpha3-D154A, predicted to be in the second N-terminal repeat not known to be implicated in cell adhesion, was competent for invasin-promoted adhesion events and appeared to encode a receptor of increased activity, as it had a higher efficiency than wild type receptor for adhesion to epiligrin. Cell lines expressing this derivative were not recognized by a function blocking anti-alpha3 antibody, indicating that the second and third repeats of the alpha3 chain are either closely linked in space or the second repeat can modulate activity of the third. Differential effects on substrate adhesion do not appear to be associated with all integrin alpha chain mutations, as alpha4 chain mutations affecting the divalent cation binding domains depressed adhesion to invasin to a significant extent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822651     DOI: 10.1074/jbc.273.48.31837

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Fine mapping of inhibitory anti-alpha5 monoclonal antibody epitopes that differentially affect integrin-ligand binding.

Authors:  L Burrows; K Clark; A P Mould; M J Humphries
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  A role for Salmonella fimbriae in intraperitoneal infections.

Authors:  R A Edwards; D M Schifferli; S R Maloy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5.

Authors:  Barbara Salone; Yuri Martina; Stefania Piersanti; Enrico Cundari; Gioia Cherubini; Laure Franqueville; Cristina M Failla; Pierre Boulanger; Isabella Saggio
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 4.  Integrin α3β1 as a breast cancer target.

Authors:  Sita Subbaram; C Michael Dipersio
Journal:  Expert Opin Ther Targets       Date:  2011-08-13       Impact factor: 6.902

Review 5.  Physiological and pathological roles of alpha3beta1 integrin.

Authors:  Tsutomu Tsuji
Journal:  J Membr Biol       Date:  2004-08-01       Impact factor: 1.843

6.  Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method.

Authors:  Nianhuan Yao; Wenwu Xiao; Xiaobing Wang; Jan Marik; See Hyoung Park; Yoshikazu Takada; Kit S Lam
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

7.  Yersinia has a tropism for B and T cell zones of lymph nodes that is independent of the type III secretion system.

Authors:  Joan-Miquel Balada-Llasat; Joan Mecsas
Journal:  PLoS Pathog       Date:  2006-09       Impact factor: 6.823

8.  Beta1 integrins show specific association with CD98 protein in low density membranes.

Authors:  T V Kolesnikova; B A Mannion; F Berditchevski; M E Hemler
Journal:  BMC Biochem       Date:  2001-10-15       Impact factor: 4.059

9.  A role for activated Cdc42 in glioblastoma multiforme invasion.

Authors:  Hidehiro Okura; Brian J Golbourn; Uswa Shahzad; Sameer Agnihotri; Nesrin Sabha; Jonathan R Krieger; Carlyn A Figueiredo; Alan Chalil; Natalie Landon-Brace; Alexandra Riemenschneider; Hajime Arai; Christian A Smith; Songli Xu; Stefan Kaluz; Adam I Marcus; Erwin G Van Meir; James T Rutka
Journal:  Oncotarget       Date:  2016-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.